Revalesio Corporation   Report issue

For profit Phase 1 Phase 2
Founded: Tacoma WA United States (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2012
NCT01511302
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Revalesio Corporation

Active Ingredients

Drugs in Phase 2 Trials (2)

interferon beta-1b (betaseron) (1 trial)

sodium chloride (4 trials)

Drugs in Phase 1 Trials (1)

budesonide (rhinocort) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 1)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3